Scholars Central

Research articlePublished 8 May 2023

Reduced Mortality, Complications, and Economic Burden among Medicare Beneficiaries Receiving Influenza Antivirals

Authors: Jennie H Best, Sheila R Reddy, Eunice Chang, Katalin Bognar, Marian H Tarbox, Steven E Cagas, Arpamas Seetasith

Ask about this article

Abstract

Select any words in the title or abstract, or press this and choose a sentence.

Objectives: Despite evidence of potential benefits, antiviral therapy may be underutilized in patients at high risk for complications, morbidity, and increased healthcare costs (e.g., older adults). The study’s objective was to examine the clinical and economic benefits associated with antiviral treatment of seasonal influenza among treated and untreated Medicare beneficiaries. Methods: This retrospective study of Medicare claims research identifiable files identified patients ≥ 66 years old with an influenza diagnosis in outpatient setting between October 2016 and March 2019 (flu seasons 2016-2018). The index date was defined as the date of the first claim with influenza diagnosis; baseline was defined as the 12 months pre-index. Treated patients received antivirals (oseltamivir, baloxavir marboxil, peramivir or zanamivir) ≤ 2 days from index. Untreated patients had no antivirals ≤ 6 months post-index date. Treated/untreated patients were 1:1 propensity score matched. Patients treated with antivirals ≤ 2 months pre-index or had 10+ days of antiviral supply within ≤ 10 days post-index were excluded. Outcomes (death, all-cause and respiratory-related Healthcare Resource Utilization (HCRU) and costs) were assessed until death or up to 6 months post-index. Descriptive statistics were reported; Kaplan-Meier estimation was used for survival over time. Results: The final cohort contained 116,901 matched patient pairs. All cause mortality within 6 months from index diagnosis was 1.6% among treated versus 4.3% among untreated patients. Rates (treated versus untreated) of all-cause inpatient hospitalizations during follow-up were 13.9% versus 22.7%; rates of respiratory-related hospitalizations were 4.2% versus 9.0%. Mean and Standard Deviation (SD) total all-cause and respiratory-related costs were $9,830 ($18,616.0) and $900 ($4,016.4) among the treated, respectively, versus $13,207 ($24,405.1) and $2,024 ($7,623.7) among untreated, respectively. All differences were statistically significant (p<0.001). Conclusion: Lack of antiviral treatment is associated with increased mortality, HCRU, and economic burden in older Medicare beneficiaries with seasonal influenza. Future research should investigate whether the choice of antivirals affects influenza burden.

Ask about this article

Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. Scholars Central does not store it.

Try:

More from this journal

The newest in Journal of Infectious Diseases and Diagnosis.

All its articles

Conferences in this field

Upcoming conferences in this field.

Follow

New articles from what you follow go into your email digest, once you agree to alert emails.

  • JournalJournal of Infectious Diseases and Diagnosis
  • SubjectInfectious Diseases
  • BylineArticles whose byline prints “Jennie H Best”
  • BylineArticles whose byline prints “Sheila R Reddy”
  • BylineArticles whose byline prints “Eunice Chang”
  • BylineArticles whose byline prints “Katalin Bognar”
  • BylineArticles whose byline prints “Marian H Tarbox”
  • BylineArticles whose byline prints “Steven E Cagas”
  • BylineArticles whose byline prints “Arpamas Seetasith”